• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Bristol Myers Squibb Expands at Cambridge Crossing

    Amgen Completes Five Prime Acquisition

    Sartorius Expands in the UK

    Obituary Notice: Russell “Russ” Haines

    Abenza Chooses North Carolina for New Biologics Manufacturing Site
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Abenza Chooses North Carolina for New Biologics Manufacturing Site

    Catalent Adds Cryogenic Capabilities at Philadelphia Facility

    Recro, Ensysce Expand Development and Manufacturing Partnership

    Metrics Names Stephanie Emory Associate Director of Pharma Development

    Albumedix Completes Commercial-Scale Mfg. Facility Expansion
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Obituary Notice: Russell “Russ” Haines

    Catalent Adds Cryogenic Capabilities at Philadelphia Facility

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!

    Securing Your API Supply Chain: Three Keys to Success
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Bristol Myers Squibb Expands at Cambridge Crossing

    Amgen Completes Five Prime Acquisition

    Sartorius Expands in the UK

    Abenza Chooses North Carolina for New Biologics Manufacturing Site

    Arkema Recruits Dotmatics as its R&D Digitalization Partner
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Ensuring Pharma Manufacturing Quality

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations

    Enteris BioPharma: Custom Solutions – From Bench to Market
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Quotient Sciences

    Emergent BioSolutions

    Almac Group

    PCI Pharma Services

    Alcami
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Reed-Lane

    Syngene

    Aphena Pharma Solutions

    Adare Pharma Solutions

    PCI Pharma Services
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Top Companies Report

    08 AbbVie

    ...

    08	AbbVie
    bye
    Related CONTENT
    • Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie
    • AbbVie, Caribou Ink CAR-T Collaboration
    • AbbVie Licenses ProBioGen’s GlymaxX Technology
    • Summit Therapeutics Appoints Chief Operating Officer
    • Mogene
    07.20.18
    Headquarters: North Chicago, IL
    twitter.com/abbvie
    www.abbvie.com

    Headcount:  29,000
    Year Established: 2013
    Revenues:  $28,216  (+10%)
    Net Income:  $5,309  (-11%)
    R&D:  $4,982  (+14%)

    TOP SELLING DRUGS   
    Drug Indication 2017 Sales (+/-%)
    Humira rheumatoid arthritis $18,427 15%
    Imbruvica chronic lymphocytic  leukemia $2,573 40%
    Viekira hepatitis C $1,274 -16%
    Creon digestion $831 12%
    Lupron hormone treatment $829 1%
    Synthroid hyperthyroidism $781 2%
    Synagis RSV $738 1%
    AndroGel testosterone $577 -15%
    Kaletra HIV/AIDS $423 23%
    Sevoflurane anesthesia $410 -4%

    Last year marked Abbvie’s fifth in operation and proved to be its most successful since it launched in 2013. Revenues grew by 10 percent to $28.2 billion, marking the third consecutive year of double-digit growth driven by blockbuster Humira.

    With 15% growth year-over-year and $18.4 billion in 2017 sales, Humira is the world’s best-selling drug and accounted for approximately 65% of AbbVie’s total 2017 revenue. As the most widely prescribed autoimmune biologic therapy, Humira will continue to be an important growth driver for several years. EvaluatePharma says the rheumatoid arthritis drug will continue to top the revenue charts through 2022.

    AbbVie’s positive growth can also be attributed to cancer drug Imbruveca’s 40% jump in sales to $2.5 billion. Other key products include Creon and Duodopa and the launch of HCV product Mavyret. These increases were partially offset by a decline in net revenues of HCV product Viekira due to heavy competition.

    Pipeline approvals
    With regards to its pipeline, AbbVie has more than 60 programs exploring new technologies and approaches to treatment in active clinical development across key therapeutic areas and remains on track to launch more than 20 new products or indications by 2020.

    In January 2017, the FDA approved Imbruveca for patients with relapsed/refractory marginal zone lymphoma who require systemic therapy and have received at least one prior anti-CD20-based therapy. This indication was approved under accelerated approval based on overall response rate (ORR) and continued approval may be contingent upon verification and description of clinical benefit in a confirmatory trial. MZL is a slow-growing form of non-Hodgkin’s lymphoma.

    In August 2017, the FDA also approved Imbruveca for the treatment of adult patients with chronic graft- versus-host-disease (cGVHD) after failure of one or more lines of systemic therapy. Imbruveca is the first therapy specifically approved for adults with cGVHD, a severe and potentially life-threatening consequence of stem cell or bone marrow transplant. This marked the sixth U.S. disease indication for Imbruveca since the medication’s initial approval in 2013 and the first approved indication outside of cancer.

    In the same month, the FDA approved Mavyret for the treatment of patients with chronic HCV genotype 1-6 infection without cirrhosis and with compensated cirrhosis (Child-Pugh A). Mavyret is also indicated for the treatment of adult patients with HCV genotype 1 infection.

    Advancing early stage research
    After acquiring Stemcentrx and its lead late-stage asset Rova-T for $5.8 billion in 2016, AbbVie was not active in M&A in 2017. The company instead focused on developing new collaborations to advance early-stage research in key therapeutic areas such as oncology and immunology.

    With WuXi NextCODE, a global contract genomics organization, AbbVie entered a 15-year strategic alliance to conduct population genomics research in Ireland aimed at advancing the discovery and development of new therapeutic approaches for serious diseases within oncology, neuroscience and immunology. The alliance will result in the sequencing of 45,000 genomes from volunteers across Ireland to seek novel insights into the biological processes that underlie complex disease. AbbVie will use the research database developed by GMI to identify new molecular approaches for drug discovery and development as well as companion diagnostics.

    AbbVie and Pure MHC entered a research and license agreement to discover and validate peptide targets for use with T-cell receptor therapeutics in several types of cancers.Pure MHC has developed technology to identify novel, tumor-associated peptides based on innovation licensed from the University of Oklahoma. The collaboration aims to identify a library of peptide targets for further research across multiple tumor types and advance AbbVie’s next-gen immuno-oncology therapies.

    AbbVie also entered into an exclusive license with Dong-A-ST, a specialty healthcare company in South Korea, for MerTK inhibitors in preclinical development for use in conjunction with immuno-oncology therapies. MerTK is a protein that is believed to contribute to the promotion of immunosuppressive tumor microenvironment. The collaboration will explore the combination of MerTK inhibitors in conjunction with AbbVie’s portfolio of anti-cancer agents across multiple types of solid tumors.

    In addition, a partnership with Zebra Biologics aims to discover agonist antibody therapeutics for inflammatory diseases. Zebra will use its function-based antibody discovery platform to generate antibodies that activate biological pathways associated with AbbVie targets. The companies will collaborate on the identification and preclinical validation of emerging, undisclosed candidates. Zebra will lead the discovery of candidate agonist antibodies and will collaborate with AbbVie in preclinical validation of select clinical candidates. AbbVie would be responsible for clinical development, manufacturing, regulatory approval and commercialization.

    Lastly, AbbVie and Turnstone Biologics entered a research, option and license agreement under which AbbVie obtained an exclusive option to license as many as three of Turnstone’s next-generation oncolytic viral immunotherapies. Oncolytic viruses take advantage of defective pathways in tumors to selectively replicate in and destroy cancer cells, while cancer vaccines create killer (CD8+) T cell immune responses against tumor antigens. 

    AbbVie has an option to obtain all global development and commercialization rights to Turnstone’s Ad-MG1-MAGEA3 therapy, in two Phase 1/2 trials for multiple solid tumor indications. Each of the three therapies leverages Turnstone’s platform based on an engineered Maraba virus. In the event AbbVie exercises one or more of its options, AbbVie expects to pursue this immunotherapeutic technology across several types of solid tumors. 
    Related Searches
    • late-stage
    • hepatitis
    • companion diagnostics
    • immuno-oncology
    Suggested For You
    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie
    AbbVie, Caribou Ink CAR-T Collaboration AbbVie, Caribou Ink CAR-T Collaboration
    AbbVie Licenses ProBioGen’s GlymaxX Technology AbbVie Licenses ProBioGen’s GlymaxX Technology
    Summit Therapeutics Appoints Chief Operating Officer Summit Therapeutics Appoints Chief Operating Officer
    Mogene Mogene
    Financial Report: Abbvie Financial Report: Abbvie
    Bioclinica Establishes Medical and Scientific Affairs Organization Bioclinica Establishes Medical and Scientific Affairs Organization
    Softweb Solutions Softweb Solutions
    Reed-Lane Reed-Lane
    Vetio Animal Health Vetio Animal Health
    Top 25 Pharma and Biopharma Companies Top 25 Pharma and Biopharma Companies
    Top 25 Pharma and Biopharma Companies Top 25 Pharma and Biopharma Companies
    WuXi NextCODE Invests $400M to Expand Precision Medicine Efforts in Ireland WuXi NextCODE Invests $400M to Expand Precision Medicine Efforts in Ireland
    Janssen Receives FDA Approval for INVOKANA Janssen Receives FDA Approval for INVOKANA
    Alcami Collaborates with Medicines Development for Global Health Alcami Collaborates with Medicines Development for Global Health

    Related Top Companies Report

    • 25 CSL Behring

      25 CSL Behring

      ...
      Kristin Brooks, Managing Editor, Contract Pharma 07.20.20

    • 22 Astellas

      22 Astellas

      ...
      Kristin Brooks, Managing Editor, Contract Pharma 07.20.20

    • 21 Biogen

      21 Biogen

      ...
      Kristin Brooks, Managing Editor, Contract Pharma 07.20.20


    • 12 Amgen

      12 Amgen

      ...
      Tim Wright, Editor, Contract Pharma 07.20.20

    • 13 Gilead Sciences

      13 Gilead Sciences

      ...
      Kristin Brooks, Managing Editor 07.15.20

    • 10 Bristol-Myers Squibb

      10 Bristol-Myers Squibb

      ...
      Kristin Brooks, Managing Editor, Contract Pharma 07.15.20


    • 03 Novartis

      03 Novartis

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    • 02 Roche

      02 Roche

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    • 09 Takeda

      09 Takeda

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20


    • 01 Pfizer, Inc.

      01 Pfizer, Inc.

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    • The 2020 Top 25 Pharma and Biopharma Companies

      The 2020 Top 25 Pharma and Biopharma Companies

      Top 25 Pharma and Biopharma Companies (Based on 2019 Pharma/Biopharma Sales, in $U.S. Millions)
      Contract Pharma Staff 07.15.20

    • 08 GlaxoSmithKline

      08 GlaxoSmithKline

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20


    • 07 AbbVie

      07 AbbVie

      ...
      Kristin Brooks , Managing Editor, Contract Pharma 07.15.20

    • 06 Sanofi

      06 Sanofi

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    • 05 Merck

      05 Merck

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    Trending
    • Thermo Fisher Acquires PPD For $17.4B
    • Ensuring Pharma Manufacturing Quality
    • Bristol Myers Squibb Expands At Cambridge Crossing
    • Abenza Chooses North Carolina For New Biologics Manufacturing Site
    • Amgen Completes Five Prime Acquisition
    Breaking News
    • Bristol Myers Squibb Expands at Cambridge Crossing
    • Amgen Completes Five Prime Acquisition
    • Sartorius Expands in the UK
    • Obituary Notice: Russell “Russ” Haines
    • Abenza Chooses North Carolina for New Biologics Manufacturing Site
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    AstaReal Astaxanthin Ingredient Receives U.S. Patent Approval
    Study on Kemin’s DailyZz Botanical Blend Uncovers Sleep Quality, Next-Day Performance Benefits
    FDA’s Dr. Cara Welch Opening Speaker at the 9th AHPA Botanical Congress
    Coatings World

    Latest Breaking News From Coatings World

    Jebsen & Jessen, Innospec Sign Distribution Agreement
    IGL Coatings Announces Partnership in Finland
    Axalta Schedules 1Q 2021 Earnings Conference Call
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Iterative Scopes Announces IBD-Focused Scientific Advisory Board
    Vicarious Surgical, D8 Holdings Corp. Combine Operations in $1.1 Billion Deal
    FDA Grants De Novo Clearance to Medtronic’s GI Genius Model
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Bristol Myers Squibb Expands at Cambridge Crossing
    Amgen Completes Five Prime Acquisition
    Sartorius Expands in the UK
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Former L’Oréal Exec Joins Glossier
    Lancôme Reveals New Global Sustainability Program
    First-Ever Skincare Line Focuses on Iron To Prevent Aging
    Happi

    Latest Breaking News From Happi

    Fragrance Creators Association Celebrates P&G Executive
    Evonik Highlights Solutions for Malodor Reduction
    P&G Emphasizes Small Actions at Home To Be More Sustainable
    Ink World

    Latest Breaking News From Ink World

    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    SE-DA Invests in Kornit Presto S
    Acrylic Resins Market Worth $21.9 Billion by 2025: MarketsandMarkets
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    TLMI reveals Eugene Singer Award winners at Virtual Spring Summit
    Monadnock Paper Mills joins SGP
    ACTEGA helps converter reach sustainability goals
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Albaad to Add Natural-Based Line in Israel
    First Quality to Discontinue Tampon Operations
    Jessup Installs New Era Coating and Laminating Line
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    BioMagnetic Sciences Names President and CEO
    Mainstay Medical Launches ReActiv8 in Australia
    Biogennix Rolls Out Agilon Strip Bone Graft
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Virtual ASMC 2021 Spotlights Advanced Semiconductor Manufacturing Excellence
    LG Display Cuts Down CO2-eq Emissions by 3 Million Tons in 2020
    European Commission's Innovation Radar Acknowledges 3 ARMOR Innovations

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login